Mr. Speaker, the minister has repeated something that concerns me a little bit. She has continued to say that the drug which the FDA had complained about with regard to contamination, manufacturing quality control, strength, et cetera, was not a drug that was used in Canada. She has never explained why Health Canada, which had looked at the manufacturing capacity of Sandoz, had given it a green light.
We all know, and this is reiterated in anything coming out of the FDA, that a manufacturing company that produces drugs uses the same equipment, the same plant and the same capacity to produce all drugs, not just one drug. Therefore, any contamination, impurities and quality control problems that occurred at Sandoz which had been flagged in 2009 should have caused the Government of Canada to say that a proper quality control inspection at Sandoz is needed because it is making many drugs, not just one product.